ReviewCurrent allergy and asthma reports2006
Indoleamine-2,3-dioxygenase modulation of allergic immune responses.
Review in Current allergy and asthma reports, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 28 citations in OpenAlex.
- Trained immunity induced by in vivo peptide-based STAT6 inhibition prevents ragweed allergy in mice.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2021Article
- Mood Worsening on Days with High Pollen Counts is associated with a Summer Pattern of Seasonality.Pteridines · 2019Article
- Nitrite, neopterin levels and tryptophan degradation in allergic conjunctivitis.International ophthalmology · 2018Article
- TGF-β-mediated airway tolerance to allergens induced by peptide-based immunomodulatory mucosal vaccination.Mucosal immunology · 2015Article
- α-Tocopherol supplementation of allergic female mice inhibits development of CD11c+CD11b+ dendritic cells in utero and allergic inflammation in neonates.American journal of physiology. Lung cellular and molecular physiology · 2014Article
- Airway epithelial indoleamine 2,3-dioxygenase inhibits CD4+ T cells during Aspergillus fumigatus antigen exposure.American journal of respiratory cell and molecular biology · 2011Article
- Article
- Interferon-gamma-responsive nonhematopoietic cells regulate the immune response to Mycobacterium tuberculosis.Immunity · 2009Article
- Inhibition of indoleamine 2, 3-dioxygenase-mediated tryptophan catabolism accelerates crescentic glomerulonephritis.Clinical and experimental immunology · 2009Article
- Substrate and cofactor requirements of indoleamine 2,3-dioxygenase in interferon-gamma-treated cells: utilization of oxygen rather than superoxide.Current drug metabolism · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Induction of immunologic tolerance is highly desirable in the treatment and prevention of allergy and other immune disease states in which the immune response to foreign or self antigens has become overactive. Indoleamine-2,3-dioxygenase (IDO), an enzyme classically known for its role in the tryptophan degradation pathway, has recently emerged as an important immunomodulator of T-cell function and inducer of tolerance. The induced expression of IDO by dendritic cells may suppress T-cell responses and promote tolerance either through direct effects on T cells (mediated by tryptophan depletion or tryptophan metabolites) or through effects of IDO on the dendritic cell. In addition to the potential role of IDO in promoting tolerance in pregnancy, transplantation, and autoimmunity, its role in modulating allergic responses has more recently been investigated, raising the possibility that IDO and its metabolites may be novel targets for immunomodulation in allergy and asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.